Systemic therapy for breast cancer is determined from the presence or absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor II (HER2) status as well as pathological factors such as nuclear grade and Ki-67 expression. This evidence concerns the gene ERBB2 and breast cancer.